Phase 3 Clinical Trials With Primary Completion Dates in July 2021

This is a list of Phase 3 trials with primary completion dates in July 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ADILAdial Pharmaceuticals, Inc.2021-07-01Phase 3NCT04101227Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
BBIBrickell Biotech, Inc.2021-07-01Phase 3NCT03836287Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
BFRABiofrontera AG2021-07-01Phase 3NCT03573401Study to Evaluate the Safety and Efficacy of BF-200 ALA (AmeluzĀ®) and BF-RhodoLEDĀ® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
CURRCURE Pharmaceutical Holding Corp.2021-07-01Phase 3NCT04668950Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
HLUYYH. Lundbeck A/S2021-07-01Phase 3NCT04418765A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Patients That Are Not Helped by Previous Preventive Treatments
HRTXHeron Therapeutics, Inc.2021-07-01Phase 3NCT03907176Herniorrhaphy Study for Opioid Elimination
ICPTIntercept Pharmaceuticals, Inc.2021-07-01Phase 3NCT03439254Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
LNTHLantheus Holdings, Inc.2021-07-01Phase 3NCT02764801Contrast-enhanced Ultrasound Evaluation of Chemoembolization
MEDDMedical Imaging Corp.2021-07-01Phase 3NCT02764801Contrast-enhanced Ultrasound Evaluation of Chemoembolization
MIRMMirum Pharmaceuticals, Inc.2021-07-01Phase 3NCT03905330A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)